Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.08% | 5.02% | -9.83% | 22.16% | 25.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.58% | 171.02% | 12.98% | 86.38% | 120.96% |
| Operating Income | -104.58% | -171.02% | -12.98% | -86.38% | -120.96% |
| Income Before Tax | -116.83% | -207.84% | -21.06% | -99.82% | -121.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.83% | -207.84% | -21.06% | -99.82% | -121.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.83% | -207.84% | -21.06% | -99.82% | -121.84% |
| EBIT | -104.58% | -171.02% | -12.98% | -86.38% | -120.96% |
| EBITDA | -104.80% | -171.64% | -13.03% | -86.74% | -121.69% |
| EPS Basic | -62.43% | -150.80% | -20.62% | -67.32% | -52.65% |
| Normalized Basic EPS | -62.45% | -150.79% | -20.62% | -67.31% | -52.59% |
| EPS Diluted | -62.43% | -150.80% | -20.62% | -67.32% | -52.65% |
| Normalized Diluted EPS | -62.45% | -150.79% | -20.62% | -67.31% | -52.59% |
| Average Basic Shares Outstanding | 33.49% | 22.75% | 0.35% | 19.44% | 45.34% |
| Average Diluted Shares Outstanding | 33.49% | 22.75% | 0.35% | 19.44% | 45.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |